AXIM Biotechnologies Company Description

AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases.

The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests.

It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.

The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.

AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

AXIM Biotechnologies, Inc.

Country	United States
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	John Huemoeller

Contact Details

Address: 6191 Cornerstone Court, East San Diego, Nevada 92121 United States
Phone	858 923 4422
Website	aximbiotech.com

Stock Details

Ticker Symbol	AXIM
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US05463V1008
SIC Code	2835

Key Executives

Name	Position
Catalina Valencia J.D.	President and Director
Robert T. Malasek	Chief Financial Officer and Secretary
Kurt Phinney	Chief Operating Officer
Dr. Sergei A. Svarovsky M.B.A., Ph.D.	Chief Scientific Officer and Co-Founder of Sapphire Biotech, Inc.
Dr. Douglas Lake Ph.D.	Chief Clinical Officer of Sapphire Biotech, Inc.
Dr. Alim Seit-Nebi Ph.D.	Chief Technology Officer and Co-Founder of Sapphire Biotech, Inc.
Jeffrey A. Busby	Senior Vice President of Business Development
Dr. Joseph Tauber M.D.	Chief Medical Officer and Chairman of the Medical Advisory Board
Dr. Maria J. Gonzalez Moa Ph.D.	Vice President of Product Development - Sapphire Biotech, Inc.